Cerebral small vessel disease (CSVD) is a condition in which the tiny arteries, capillaries, and veins deep inside the brain gradually deteriorate, disrupting blood flow to regions that handle thinking, movement, and mood. It is among the most common findings on brain MRIs in people over 60 and is responsible for roughly half of all dementia cases worldwide as well as a significant share of strokes. The condition usually develops silently over years, and many people learn about it only when a scan ordered for something else reveals telltale white spots in the brain’s deep tissue. Understanding what drives it and what you can realistically do about it matters, because the window for slowing its progression is widest before symptoms become obvious.
What Is Actually Happening Inside the Brain
The brain’s deep white matter and subcortical structures are fed by small penetrating arterioles that branch off from larger surface arteries and dive straight down through the cortex. Each of these tiny vessels supplies its own column of tissue, with very little sharing of blood flow between neighboring columns.
That limited backup supply is the core vulnerability. Research has shown that penetrating arterioles act as a bottleneck: if one becomes narrowed or blocked, the tissue it feeds has almost no way to compensate by drawing blood from a neighbor.
In CSVD, the walls of these small vessels thicken and stiffen over time. The most common pattern is a concentric, fibrotic thickening called arteriolosclerosis, typically affecting vessels up to about 300 microns in diameter. Less common variants include small-artery atheroma and a fatty degeneration of the vessel wall known as lipohyalinosis. All of these changes restrict the flow of blood and oxygen to the surrounding brain tissue.
A key early event appears to be failure of the blood-brain barrier, the tightly sealed lining of brain blood vessels that normally keeps harmful substances out. One cohort study found evidence that barrier breakdown is an early step in the disease process, with leakage triggering ongoing vessel-wall injury, inflammation, impaired blood-flow regulation, and further narrowing of the vessel, creating a self-reinforcing cycle of damage. Animal research supports this sequence, suggesting that endothelial injuries lead to multiple sites of barrier leakage that progressively weaken the vessel wall and can eventually result in tiny bleeds.
Symptoms You Might Notice and Symptoms You Might Not
The frustrating reality of CSVD is that it often causes no obvious symptoms for years. The damage accumulates quietly in brain regions that handle behind-the-scenes processing rather than dramatic functions like speech or vision. When symptoms do emerge, they tend to creep in gradually rather than arriving all at once.
The earliest and most consistent cognitive change is a slowdown in processing speed. Tasks that require you to juggle information quickly, shift between mental tasks, or hold multiple items in working memory become harder. Multiple studies confirm that the white matter damage seen in CSVD is specifically associated with decline in processing speed and executive function. One study following older adults over time found that these structural brain changes predicted decline in information processing speed and executive function more than they predicted memory loss. Memory problems can develop later, but the initial hit is usually to the speed and flexibility of thinking rather than to recall.
Walking and balance problems are another hallmark that often goes unrecognized. CSVD can disrupt gait both by affecting motor pathways directly and by impairing the cognitive control that steady walking requires. Research suggests that damage to pathways connecting deep brain structures to the cortex may be the common thread linking the cognitive, motivational, and movement problems seen in the disease. Apathy, a marked loss of motivation and initiative, frequently accompanies the cognitive and gait changes and appears to share the same underlying pathway damage.
Depression is also part of the picture. A large population study found that most markers of CSVD progression over time, and some baseline markers, were associated with the development of new depressive symptoms, supporting the idea that vascular damage to mood-regulating brain circuits can trigger what researchers call “vascular depression.”
Why Some People With Extensive Damage Stay Sharp
One of the puzzles of CSVD is the loose connection between what the brain scan shows and how the person actually functions. Two people can have similar-looking white matter damage, yet one is managing daily life independently while the other is struggling. Research points to cognitive reserve as a major reason for this gap. Education and occupational complexity appear to buffer the brain against the clinical impact of the disease. A long-term study found that the harmful effect of white matter damage on processing speed and memory was moderated by education and occupation, and that higher attainment in both predicted better functional independence and lower mortality at seven-year follow-up. In general, higher educational attainment appears to soften the blow that white matter damage deals to cognition.
This does not mean that education protects against the disease itself. The vessels still deteriorate. But people with greater cognitive reserve seem able to reroute mental work through intact networks for longer before the damage becomes debilitating. From a practical standpoint, staying intellectually and socially engaged throughout life is one of the few things within your control that may stretch the period between silent brain changes and noticeable symptoms.
The Main Causes and Risk Factors
High blood pressure is far and away the dominant modifiable cause. Chronic hypertension drives the arteriolar-wall thickening, blood-brain barrier breakdown, and chronic low-grade ischemia that define the most common form of the disease. The histopathological changes linked to hypertension include arteriolar wall thickening, barrier breakdown, and ongoing reduced blood supply to deep brain tissue. If there is a single message about prevention, it is that controlling blood pressure early and consistently matters more than almost anything else.
The second major form of CSVD is cerebral amyloid angiopathy (CAA), in which beta-amyloid protein deposits build up in the walls of small arteries and capillaries at the brain’s surface and in the membranes surrounding it. CAA is a major cause of lobar brain hemorrhage and cognitive impairment in older adults, and it is associated with a high prevalence of cerebral microbleeds and white matter damage on MRI. CAA is distinct from hypertension-related CSVD in both its mechanism and its typical brain-scan pattern: microbleeds from CAA tend to cluster in the outer cortex, while those caused by hypertensive damage appear deeper in the brain. One study found that strictly intracortical microbleeds were strongly associated with CAA even after adjusting for other imaging features, while any combination of lobar and deep microbleeds pointed toward hypertensive disease.
Beyond hypertension and amyloid, several other risk factors overlap with those for heart disease and stroke:
- Diabetes: chronically elevated blood sugar damages small-vessel walls throughout the body, including the brain.
- Aging: vessel stiffening and barrier weakening accelerate with age, making CSVD almost universal to some degree in very old adults.
- Obesity and poor sleep: both are linked to inflammation and impaired clearance of brain waste.
Emerging research highlights the brain’s waste-clearance system, sometimes called the glymphatic system, as another piece of the puzzle. Fluid flows along spaces surrounding blood vessels (perivascular spaces), flushing out metabolic waste during sleep. CSVD and glymphatic dysfunction share many of the same risk factors, and the disease appears to hinder waste clearance. Dilated perivascular spaces visible on MRI are now recognized as a marker of this disruption. The relationship may be bidirectional: poor clearance could accelerate vessel damage, and vessel damage could further impair clearance.
Genetic Forms
Most CSVD develops gradually from the risk factors described above, but a small fraction is caused by single-gene mutations that damage small vessels much earlier in life. The best known is CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy), caused by mutations in the NOTCH3 gene. CADASIL is the most common monogenetic form of small vessel disease and a major cause of hereditary vascular dementia. It typically produces migraine with aura in the 20s or 30s, followed by recurrent small strokes, mood disturbances, and progressive cognitive decline.
Recent laboratory work using stem-cell-derived models has revealed why the disease hits brain vessels specifically: brain-origin smooth muscle cells carrying NOTCH3 mutations are selectively vulnerable compared with smooth muscle cells from other parts of the body. The affected cells shift to an abnormal state, accumulating excess material outside the cell and losing their ability to adhere properly, ultimately leading to cell death. Understanding this selectivity has opened doors to potential treatments. The same research found that a class of drug already used for other vascular conditions, phosphodiesterase-5 inhibitors, could rescue some of the damage in the lab model. Additionally, investigation into the metabolic consequences of specific NOTCH3 mutations has identified impaired growth-factor signaling as a contributor to endothelial cell degeneration, and an existing neuroprotective drug (edaravone dexborneol) showed therapeutic effects in both hereditary and non-hereditary models of the disease.
How Doctors Spot It on Brain Scans
CSVD is overwhelmingly a diagnosis made by brain imaging, usually MRI. A standardized reporting framework called STRIVE has organized the visible features into a common vocabulary. The main markers radiologists look for include white matter hyperintensities (bright spots in the brain’s deep wiring), recent small subcortical infarcts, lacunes (small fluid-filled cavities left by old infarcts), enlarged perivascular spaces, cerebral microbleeds, superficial siderosis, cortical microinfarcts, and brain atrophy.
Of these, white matter hyperintensities are by far the most common finding and the one most strongly linked to cognitive decline. But conventional MRI can miss subtler damage. Advanced techniques such as diffusion tensor imaging can detect loss of structural integrity in white matter that looks normal on a standard scan, picking up changes in how freely water molecules move through brain tissue. When the internal architecture of white matter fibers breaks down, water diffuses more freely in all directions rather than flowing along the fiber tracts, and these changes have been linked to worse cognitive performance.
One of the more intriguing developments is the use of retinal imaging as a window into brain vessel health. The tiny blood vessels in the back of the eye share developmental and structural features with those in the brain, and several recent studies have found that geometric characteristics of retinal blood vessels are associated with a greater burden of CSVD markers on brain MRI. A study within the large ARIC cohort reported that midlife retinal microvascular abnormalities may be a valuable indicator of late-life CSVD, suggesting that a routine eye photograph could one day help flag people at risk years before a brain scan would show problems. Structural changes in specific retinal layers, including thinning of the ganglion cell layer, have also been observed in CSVD patients compared with age-matched controls.
Prevention Through Blood Pressure Control
The strongest evidence for slowing CSVD comes from aggressive blood pressure management. The landmark SPRINT-MIND trial compared intensive blood pressure treatment (targeting a systolic reading below 120 mmHg) with standard treatment (below 140 mmHg) in adults at high cardiovascular risk. Brain imaging showed that intensive treatment was associated with a significantly smaller increase in white matter lesion volume over the follow-up period. A post-hoc regional analysis of the same trial confirmed that the benefit was especially pronounced in the brain’s deep white matter regions, with areas like the corona radiata and posterior thalamic radiation showing roughly half the lesion growth under intensive treatment compared with standard care.
These findings are important because white matter lesions in CSVD were long assumed to be irreversible and steadily progressive. Intensive blood pressure control did not reverse existing damage, but it meaningfully slowed the accumulation of new damage. For someone in their 50s or 60s with early signs of CSVD on a scan, the difference between controlled and uncontrolled blood pressure could translate into years of preserved cognitive function.
Diet, Exercise, and Other Lifestyle Factors
Blood pressure control is the headline, but it is not the whole story. Physical activity has shown neuroprotective effects in animal models of CSVD, with mechanisms including increased brain plasticity, stronger blood vessel integrity, reduced inflammation and oxidative stress, and improved white matter health. While translating animal findings to humans always requires caution, the consistency of the benefits across multiple disease models is encouraging, and the broader evidence linking regular exercise to better brain health in aging is strong enough to make it a reasonable recommendation on its own merits.
Diet also appears to play a moderating role. A study in older adults found that healthy dietary intake moderated the association between CSVD biomarkers and cognitive test scores: the expected negative relationship between vessel disease and cognition was apparent in people with poor diets but not in those with medium or high levels of healthy eating. The effect was a moderation rather than a direct reversal, meaning a good diet did not erase the brain damage but seemed to blunt its cognitive impact, possibly through reduced inflammation or better vascular function.
The Antiplatelet Dilemma
If you have CSVD and have also had a stroke or mini-stroke, you are likely taking blood-thinning medications like aspirin or clopidogrel. This creates a genuine clinical tension. A meta-analysis found that antiplatelet therapy was associated with a higher risk of cerebral microbleeds in people who had already had a stroke. At the same time, stopping these drugs raises the risk of another ischemic stroke or heart attack.
The calculus depends heavily on how many microbleeds are already present. A large study combining two patient cohorts found that among people taking antiplatelet drugs, the five-year risk of brain hemorrhage climbed steeply with the number of existing microbleeds. In patients with five or more microbleeds, brain hemorrhages were overwhelmingly severe: about four out of five were disabling or fatal, compared with a lower proportion of disabling ischemic strokes. During the first year after a mini-stroke or ischemic stroke, the risk of another clot-related event still outweighed the hemorrhage risk even in people with many microbleeds, but after the first year the balance shifted, with hemorrhage risk matching or exceeding ischemic risk.
This is a decision that needs to be individualized. If you have been told you have many microbleeds, the conversation with your doctor about continuing antiplatelet therapy is worth having, particularly if more than a year has passed since your last ischemic event.
The Overlap With Alzheimer’s Disease
CSVD and Alzheimer’s disease were once treated as entirely separate conditions, one vascular and the other neurodegenerative. That boundary has blurred considerably. Epidemiological and clinical-pathological studies have found evidence of a relationship between the two. One study found that the presence of both microbleeds and white matter damage was associated with lower levels of a key Alzheimer’s biomarker in cerebrospinal fluid, suggesting a direct link between vascular damage and amyloid pathology. The researchers concluded that amyloid buildup appears worse in the presence of vascular damage, pointing to a synergy between the two disease processes rather than simple coexistence.
This overlap has practical consequences. It means that vascular risk-factor management, particularly blood pressure control, may not only slow CSVD but also reduce or delay the amyloid-related pathology that drives Alzheimer’s. It also means that a person diagnosed with CSVD should be monitored for cognitive changes that go beyond the typical processing-speed decline, since the two diseases may be feeding each other.
Emerging Therapeutic Research
Current treatment for CSVD is almost entirely about risk-factor management. There are no approved drugs that directly target the damaged small vessels. But early-stage research has produced some promising leads. In a rat model of CSVD, treatment with drugs that stabilize the endothelial cells lining blood vessels reversed both the vascular damage and the associated damage to oligodendrocytes, the cells responsible for maintaining the brain’s white matter insulation. That reversal is significant because it suggests the damage may not be a one-way street, at least in its earlier phases.
The glymphatic system is another area attracting therapeutic interest. Because impaired waste clearance and CSVD appear to worsen each other, interventions that improve glymphatic flow, whether through better sleep, specific body positioning during sleep, or pharmacological approaches, are being explored as potential ways to interrupt the cycle. Research has identified that CSVD and glymphatic dysfunction share risk factors including hypertension, diabetes, advanced age, poor sleep, obesity, and neuroinflammation, which suggests that treatments targeting these shared drivers might benefit both systems simultaneously.
For the inherited forms, the laboratory finding that phosphodiesterase-5 inhibitors can rescue brain-specific smooth muscle cell damage caused by NOTCH3 mutations has generated excitement, though the leap from a stem-cell model to a clinical treatment is substantial. Similarly, the identification of impaired VEGF signaling as a mechanism in CADASIL-related endothelial damage opens a new avenue for drug development, though clinical trials are still in the future.
Retinal Screening as an Early Warning System
Perhaps the most reader-relevant development in CSVD research is the growing evidence that an eye exam could eventually serve as a screening tool. The retina is the only place in the body where small blood vessels can be observed directly and noninvasively. Multiple studies have now linked retinal vascular changes to the brain-scan markers of CSVD. In older adults, geometric characteristics of retinal blood vessels correlated with greater CSVD burden on MRI. The ARIC study, which followed participants from midlife into old age, found that retinal abnormalities detected decades earlier predicted CSVD markers on later brain scans, suggesting the retinal changes precede detectable brain damage.
Structural measurements of retinal layers using optical coherence tomography have added another dimension. Patients with CSVD showed significantly reduced ganglion cell layer volume compared with age-matched controls, and specific retinal-layer changes correlated with the severity of white matter lesions. None of this is ready for clinical use as a standalone screening tool yet, but the consistency of findings across different study designs and imaging techniques suggests that retinal screening for brain vascular risk could become routine in the coming years, particularly for people with hypertension or diabetes who are already getting regular eye exams.